5Dent R, Trudeau M, Pfitchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence [J]. Clin Cancer Res,2007,13(15) :4429-4434.
二级参考文献18
1Mersin H, Yildirim E, Berberoglu U, et al. The prognostic importance of triple negative breast carcinoma [ J ]. Breast, 2008, 17(4) : 341 -346.
2Eneman, JD, Wood ME, Muss HB, Selecting adjuvant endocrine therapy for breast cancer [ J ]. Oncology, 2004,18 (14) : 1733 -1744.
3Michaud LB. Treatment-experienced breast cancer [ J ]. Am J Health Syst Pharm, 2008, 65 ( 10 Suppl 3 ) :4 - 9.
4Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase Ⅱ trial[J]. Oncology, 2002,62(1): 2-8.
5Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, muhicenter, prospective, randomized phase Ⅲ trial[J]. J Clin Oncol, 2005,23(7) : 1401 - 1408.
6Haider K, Kornek GV, Kwasny W, et al. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor[ J]. Breast Cancer Res Treat, 1999,55(3) : 203 -211.
7Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer[J]. J Clin Oncol, 1995,13(10) : 2567 -2574.
8Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma [ J ]. Cancer, 2001,92 (9) : 2267 - 2272.
9Valenza R, Leonardi V, Gebbia V, et al. Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study[ J]. Ann Oncol, 2000,11 (4) : 495 - 496.
10Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase Ⅱ trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer[J]. J Clin Oncol, 2002,20( 1 ) : 37 -41.
